- Home
- ELAB vs XBIO Comparison
ELAB vs XBIO Comparison
Compare ELAB & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- XBIO
- Stock Information
- Founded
- ELAB 2020
- XBIO N/A
- Country
- ELAB United States
- XBIO United States
- Employees
- ELAB N/A
- XBIO N/A
- Industry
- ELAB
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- XBIO Health Care
- Exchange
- ELAB Nasdaq
- XBIO Nasdaq
- Market Cap
- ELAB 6.6M
- XBIO 6.3M
- IPO Year
- ELAB 2023
- XBIO N/A
- Fundamental
- Price
- ELAB $1.65
- XBIO $4.03
- Analyst Decision
- ELAB
- XBIO Hold
- Analyst Count
- ELAB 0
- XBIO 1
- Target Price
- ELAB N/A
- XBIO N/A
- AVG Volume (30 Days)
- ELAB 4.6M
- XBIO 4.8K
- Earning Date
- ELAB 03-28-2025
- XBIO 03-20-2025
- Dividend Yield
- ELAB N/A
- XBIO N/A
- EPS Growth
- ELAB N/A
- XBIO N/A
- EPS
- ELAB N/A
- XBIO N/A
- Revenue
- ELAB $2,446,161.00
- XBIO $2,523,427.00
- Revenue This Year
- ELAB N/A
- XBIO N/A
- Revenue Next Year
- ELAB N/A
- XBIO N/A
- P/E Ratio
- ELAB N/A
- XBIO N/A
- Revenue Growth
- ELAB 112.17
- XBIO 7.15
- 52 Week Low
- ELAB $1.60
- XBIO $2.78
- 52 Week High
- ELAB $166.00
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- ELAB 39.27
- XBIO 45.61
- Support Level
- ELAB $1.60
- XBIO $3.91
- Resistance Level
- ELAB $1.80
- XBIO $4.24
- Average True Range (ATR)
- ELAB 0.11
- XBIO 0.17
- MACD
- ELAB 0.04
- XBIO -0.01
- Stochastic Oscillator
- ELAB 15.66
- XBIO 28.93
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.